Sidney Kennedy


Scientist, Li Ka Shing Knowledge Institute

Research Programs


Dr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, the Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, and a Scientist at Li Ka Shing Knowledge Institute and Toronto Western Research Institute, Toronto, Canada. Dr. Kennedy is the lead investigator for a large depression biomarker initiative. He has published extensively on new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and treatment guidelines for Major Depressive Disorder and Bipolar Disorder.

Dr. Kennedy is the Immediate Past President of the International Society for Affective Disorders, former President of the Canadian College of Neuropsychopharmacology, and the founding chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT).

He has published more than 350 peer reviewed publications and 11 books on depression and related topics.

Recent Publications

  1. Ohuma, EO, Villar, J, Feng, Y, Xiao, L, Salomon, L, Barros, FC et al.. Fetal growth velocity standards from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. Am. J. Obstet. Gynecol. 2020; :. doi: 10.1016/j.ajog.2020.07.054. PubMed PMID:32768431 .
  2. Tshivuila-Matala, COO, Honeyman, S, Nesbitt, C, Kirtley, S, Kennedy, SH, Hemelaar, J et al.. Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis. AIDS. 2020;34 (11):1643-1656. doi: 10.1097/QAD.0000000000002593. PubMed PMID:32701581 .
  3. Fung, R, Villar, J, Dashti, A, Ismail, LC, Staines-Urias, E, Ohuma, EO et al.. Achieving accurate estimates of fetal gestational age and personalised predictions of fetal growth based on data from an international prospective cohort study: a population-based machine learning study. Lancet Digit Health. 2020;2 (7):e368-e375. doi: 10.1016/S2589-7500(20)30131-X. PubMed PMID:32617525 PubMed Central PMC7323599.
  4. Uher, R, Frey, BN, Quilty, LC, Rotzinger, S, Blier, P, Foster, JA et al.. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report. J Clin Psychiatry. 2020;81 (4):. doi: 10.4088/JCP.20m13229. PubMed PMID:32558407 .
  5. Shakeel, MK, MacQueen, G, Addington, J, Metzak, PD, Georgopoulos, G, Bray, S et al.. White Matter Connectivity in Youth at Risk for Serious Mental Illness: A Longitudinal Analysis. Psychiatry Res Neuroimaging. 2020;302 :111106. doi: 10.1016/j.pscychresns.2020.111106. PubMed PMID:32505905 .
  6. Farris, MS, Shakeel, MK, MacQueen, G, Goldstein, BI, Wang, J, Kennedy, SH et al.. Substance use in youth at-risk for serious mental illness. Early Interv Psychiatry. 2020; :. doi: 10.1111/eip.12995. PubMed PMID:32500614 .
  7. Phillips, JL, Jaworska, N, Kamler, E, Bhat, V, Blier, J, Foster, JA et al.. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. BMC Psychiatry. 2020;20 (1):268. doi: 10.1186/s12888-020-02672-3. PubMed PMID:32487236 PubMed Central PMC7265624.
  8. Lim, B, Sproule, BA, Zahra, Z, Sunderji, N, Kennedy, SH, Rizvi, SJ et al.. Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. Int Clin Psychopharmacol. 2020;35 (5):243-253. doi: 10.1097/YIC.0000000000000316. PubMed PMID:32459725 .
  9. Dunlop, K, Rizvi, SJ, Kennedy, SH, Hassel, S, Strother, SC, Harris, JK et al.. Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology. 2020;45 (8):1390-1397. doi: 10.1038/s41386-020-0688-x. PubMed PMID:32349119 PubMed Central PMC7297974.
  10. Rosenblat, JD, Mansur, RB, Brietzke, E, Kennedy, SH, Carvalho, AF, Lee, Y et al.. Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. Psychiatry Res. 2020;288 :112967. doi: 10.1016/j.psychres.2020.112967. PubMed PMID:32339805 .
Search PubMed

Affiliations & Other Activities

  • Staff Physician, Department of Mental Health, St. Michael’s Hospital
  • Professor, Department of Psychiatry, University of Toronto
  • Research Scientist, Krembil Neurosciences, University Health Network